| 臺大學術典藏 |
2021-02-23T08:26:21Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; SUNG-HSIN KUO |
| 臺大學術典藏 |
2021-02-23T08:26:11Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.;Guo J.-C.;Hsu C.;Sung-Hsin Kuo;Tien Y.-W.;Cheng A.-L.;Yeh K.-H.; Yang S.-H.; Guo J.-C.; Hsu C.; SUNG-HSIN KUO; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-02-19T06:52:27Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Hsu C.;Chih-Hung Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T08:01:17Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; JA-DER LIANG; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T08:01:15Z |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang M.-C.; Chen C.-H.; JA-DER LIANG; Tien Y.-W.; Hsu C.; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2021-02-18T08:01:12Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-04T07:16:21Z |
Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma
|
YU-TING CHANG; Hsu C.; Jeng Y.-M.; Chang M.-C.; Wei S.-C.; Wong J.-M. |
| 臺大學術典藏 |
2021-02-04T02:48:52Z |
Study on the transient response to the point-to-point motion controls on a dual-axes air-bearing planar stage
|
Kuo, F.-C.;Hsu, C.;Hsieh, M.-R.;Yen, J.-Y.;Chen, L.-C.;Chung, T.-T.;Wang, F.-C.Jia-Yush Yen;Fu-Cheng Wang; Kuo, F.-C.; Hsu, C.; Hsieh, M.-R.; Yen, J.-Y.; Chen, L.-C.; Chung, T.-T.; Wang, F.-C.; JIA-YUSH YEN; FU-CHENG WANG |
| 臺大學術典藏 |
2021-02-02T02:48:01Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; PING-NING HSU; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-02T02:47:55Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; PING-NING HSU; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-02-02T02:21:24Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; MING-SHIANG WU; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:07:01Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C.;Kun-Huei Yeh;Hong R.-L.;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.; KUN-HUEI YEH; Hong R.-L.; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:58Z |
Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL) - A very effective regimen with good patients' compliance for advanced gastric cancer
|
Cheng A.-L.; KUN-HUEI YEH; Lin J.-T.; Hsu C.; Liu M.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:52Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Kun-Huei Yeh; Hsu C.-H.; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Kun-Huei Yeh;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:50Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C.;Shen Y.-C.;Yang C.-H.;Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Liu H.-T.;Li C.-C.;Chen J.-S.;Wu C.-Y.;Cheng A.-L.; Hsu C.; Shen Y.-C.; Yang C.-H.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:48Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Kun-Huei Yeh;Lu Y.-S.;Hsu C.-H.;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; KUN-HUEI YEH; Lu Y.-S.; Hsu C.-H.; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.;Kun-Huei Yeh;Yang C.-H.;Hsu C.;Tsai Y.-C.;Hsu W.-L.;Cheng A.-L.;Hsu C.-H.; Lin C.-C.; KUN-HUEI YEH; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:45Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.;Cheng A.-L.;Hsu C.-H.;Lu Y.-S.;Hsu C.;Kun-Huei Yeh;Wu C.-Y.;Huang C.-S.;Yang C.-H.; Lin C.-C.; Cheng A.-L.; Hsu C.-H.; Lu Y.-S.; Hsu C.; KUN-HUEI YEH; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; Hsu C.; Cheng W.-F.; Lin Y.-L.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:39Z |
Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression
|
Hsu C.; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:38Z |
erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5)
|
Hsu C.;Shen Y.-C.;Cheng C.-C.;Cheng A.-L.;Hu F.-C.;Kun-Huei Yeh; Hsu C.; Shen Y.-C.; Cheng C.-C.; Cheng A.-L.; Hu F.-C.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:37Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
Chen I.C.;Hsu C.;Chen Y.C.;Chien S.F.;Kao H.F.;Chang S.Y.;Hu F.C.;Kun-Huei Yeh; Chen I.C.; Hsu C.; Chen Y.C.; Chien S.F.; Kao H.F.; Chang S.Y.; Hu F.C.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:34Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; KUN-HUEI YEH |
| 臺大學術典藏 |
2021-01-28T01:06:34Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.;Li C.-P.;Yen C.-J.;Hsu C.;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Kun-Huei Yeh;Cheng A.-L.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH; Cheng A.-L. |
